Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520225 | 0.87 | VDR (0.64) | VDR | |
| SCHEMBL13859967 | 0.85 | VDR (0.72) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13532027 | 0.84 | VDR (0.63) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14544644 | 0.79 | VDR (0.70) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL1248611 | 0.79 | VDR (0.70) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL1248608 | 0.79 | VDR (0.70) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL4165167 | 0.79 | CYP19A1 (0.35) | VDR | |
| SCHEMBL764692 | 0.78 | VDR (0.81) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL4156343 | 0.77 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL805084 | 0.77 | VDR (0.73) | VDRHDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | claimed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | VDR, CYP2R1, CYP24A1 | VDR 1/4885HDAC6 4770/4885HDAC3 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.